Kezar Life Sciences reprices executive stock options to $2.28

Kezar Life Sciences, Inc.

Compensation Committee approved repricing of 2018 Plan options to $2.28/share, the July 24 closing price.
CEO John Fowler: 2,655,000 options repriced from $3.29-$22.85; CFO Marc Belsky: 765,000 options.
CMO Noreen Roth Henig (980,000 options) and Strategic Advisor Christopher Kirk (832,500) included.
Repricing excludes options under the 2015 Plan and 2022 Inducement Plan; all other terms unchanged.
Purpose: retain key contributors and preserve cash without additional equity dilution.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.